Long-term results of a randomized controlled trial of biosimilar CT-P16 and reference bevacizumab in patients with metastatic or recurrent non-small cell lung cancer

Purpose: Data from the CT-P16 3.1 study demonstrated equivalent efficacy between CT-P16, a bevacizumab biosimilar, and European-approved reference bevacizumab (EU-bevacizumab) for the primary endpoint of objective response rate (ORR) during induction treatment in patients with metastatic or recurren...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Zoran Andric, Fedor Moiseenko, Tamta Makharadze, Alona Oleksiienko, Eduardo Yañez Ruiz, SungHyun Kim, KeumYoung Ahn, TaeHong Park, Hana Ju, Eric Hyungseok Baek, Soonbum Kwon, IlSung Chang, SinHye Kim, HyunAh Kim, EunKyung Lee, Claire Verschraegen
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Elsevier 2025-01-01
סדרה:	Cancer Treatment and Research Communications
נושאים:	Bevacizumab Biosimilar CT-P16 NSCLC Anti-VEGF
גישה מקוונת:	http://www.sciencedirect.com/science/article/pii/S2468294225001066
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!